Follicular Challenge Test to Predict Response to GnRH Agonist Triggering

NCT ID: NCT04973969

Last Updated: 2021-07-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GnRH agonist triggering is used during ART in order to reduce the risk of OHSS. Some studies described that in up to 5% of the cycles triggered with GnRH agonist, a lack of respone or suboptimal response was displayed.

The investigators aim to asses the possibility to predict the respone to ovulation triggering by the response to decapeptyl in the follicular phase of the same cycle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will use Decapeptyl on day 2 of menstruation followed by antagonist protocol.

Hormonal proflie including E2, P, LH, FSH will be measured. LH surge and the rest of the hormonal profile will be compared to day after ovulation triggering.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study group

The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.

Group Type OTHER

Decapeptyl

Intervention Type OTHER

diagnosis of predictio value

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Decapeptyl

diagnosis of predictio value

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients that undergo fertility preservation

* patients planned to freeze embryos due to PGT or surrogacy --patients at high risk for OHSS

Exclusion Criteria

* Poor ovarian response
* known hypothalamic- pituitary dysfunction
Minimum Eligible Age

20 Years

Maximum Eligible Age

41 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Assaf Harofeh MC

senior physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sarit Avraham, Dr

Role: PRINCIPAL_INVESTIGATOR

Asaf Harofe Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shamir medical center

Tzrifin, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sarit Avraham, Dr

Role: CONTACT

00972522371126

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sarit Avraham, Dr

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0304-20-ASF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Triggering of Follicular Maturation
NCT02916173 COMPLETED PHASE3